Zhi Tong Cai Jing·2026-02-27 11:34Core Viewpoint - Junshi Biosciences (01877) reported a total revenue of approximately 2.498 billion yuan for 2025, representing a year-on-year increase of 28.23% [1] - The net loss attributable to the parent company was approximately 874 million yuan, narrowing by 31.74% year-on-year, with a basic loss per share of 0.87 yuan [1] Revenue Growth - The increase in revenue was primarily driven by significant sales growth of the core product, Toripalimab injection (brand name: Tuoyi), in the domestic market [1] Loss Reduction - The reduction in losses was mainly due to the implementation of a stock option incentive plan in 2025, which increased share-based payment expenses [1] - The company actively executed the "quality improvement and efficiency enhancement" action plan, continuously strengthening cost control measures, focusing on the R&D pipeline, efficiently investing, reducing unit production costs, and improving sales efficiency, leading to a decrease in loss amounts compared to the same period last year [1]